This article was originally published in The Gray Sheet
Executive SummaryInks definitive agreement with Baxter Healthcare to acquire 100% ownership of Nexell Therapeutics. VimRx intends to unify its corporate structure with Nexell, assume the Nexell name, and relocate its headquarters to Irvine, California. In exchange for its Nexell securities, Baxter obtains 3 mil. shares of VimRx stock and other VimRx securities options. In January, Nexell's Isolex 300 stem cell selection system was found "approvable" by FDA, provided more information for labeling and inspection purposes is submitted
You may also be interested in...
Can shaving ever be “friction free”? Not according to Procter & Gamble, which challenged in a complaint to the UK Advertising Standards Authority a claim made by a British cosmetics firm FFS that it provided a “friction free” shaving experience for women via its subscription razor service.
Work has started on UK-only regulations for the medtech and medicines sectors, to ensure that the regulatory framework not only functions but can also react swiftly to needs after the UK leaves the EU. This article is part two of two.